Edition:
United Kingdom

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

3.43USD
14 Jun 2019
Change (% chg)

$-0.26 (-7.05%)
Prev Close
$3.69
Open
$3.66
Day's High
$3.66
Day's Low
$3.43
Volume
4,315
Avg. Vol
4,679
52-wk High
$15.70
52-wk Low
$2.60

Latest Key Developments (Source: Significant Developments)

Capricor Therapeutics Says It Has Put Its Hope-2 Clinical Trial On A Voluntary Dosing Hold
Wednesday, 26 Dec 2018 

Dec 26 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS SAYS ON DEC 21, CO ANNOUNCED THAT IT HAS PUT ITS HOPE-2 CLINICAL TRIAL ON A VOLUNTARY DOSING HOLD - SEC FILING.CAPRICOR THERAPEUTICS - HOPE-2 CLINICAL TRIAL ON VOLUNTARY DOSING HOLD PENDING ONGOING SAFETY REVIEW DUE TO SEVERE ALLERGIC REACTION.CAPRICOR - TRIAL'S ONGOING SAFETY REVIEW DUE TO SEVERE ALLERGIC REACTION OCCURRED DURING PATIENT INFUSION OF BLINDED INVESTIGATIONAL PRODUCT.CAPRICOR - PATIENT RESPONDED WELL TO MEDICAL TREATMENT AND IS CURRENTLY ASYMPTOMATIC.CAPRICOR THERAPEUTICS - HAS NOTIFIED FDA ABOUT ISSUE AND IS WORKING CLOSELY WITH THE FDA ON A MITIGATION PLAN.  Full Article

Capricor Therapeutics Q3 Loss Per Share $0.14
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.14.AS OF SEPTEMBER 30, 2018, COMPANY'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED APPROXIMATELY $10.4 MILLION.CAPRICOR THERAPEUTICS - BELIEVES CURRENT FINANCIAL RESOURCES SHOULD BE SUFFICIENT TO FUND OPERATIONS AND MEET FINANCIAL OBLIGATIONS INTO Q2 OF 2019.  Full Article

Capricor Q4 Earnings Per Share $0.42
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR PRESENTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE.Q4 EARNINGS PER SHARE $0.42.CAPRICOR THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS,MARKETABLE SECURITIES TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OTHERSTHROUGH Q4 OF 2018.  Full Article

Capricor Therapeutics Says ‍FDA Has Granted CAP-1002 RMAT Designation
Monday, 5 Feb 2018 

Feb 5 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS SAYS ‍FDA HAS GRANTED CAP-1002 REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION - SEC FILING.  Full Article

Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING.CAPRICOR THERAPEUTICS INC - ON DEC 20, LELAND GERSHELL GAVE NOTICE OF HIS RESIGNATION AS CHIEF FINANCIAL OFFICER OF COMPANY, EFFECTIVE JANUARY 1, 2018.  Full Article

Capricor & California Institute For Regenerative Medicine​ Entered Into Amendment 3 To CIRM Notice Loan Award
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR SAYS ‍ON DEC 11, CO, CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE​ ENTERED INTO AMENDMENT NO. 3 TO CIRM NOTICE OF LOAN AWARD - SEC FILING.CAPRICOR SAYS PURSUANT TO AMENDMENT, TOTAL LOAN BALANCE UNDER LOAN AWARD FORGIVEN BY CIRM, TERMINATING UNIT, CO'S OBLIGATION TO REPAY LOAN BALANCE​.CAPRICOR - ‍DECISION TO TERMINATE LOAN AWARD AND FORGIVE LOAN BALANCE WAS DUE TO ABANDONMENT OF ALLSTAR PROJECT AT END OF PROJECT PERIOD​.  Full Article

Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002.CAPRICOR THERAPEUTICS INC - POTENTIAL REGISTRATION TRIAL IN DUCHENNE MUSCULAR DYSTROPHY ON TRACK TO INITIATE IN Q1 OF 2018.CAPRICOR THERAPEUTICS-PLANS TO APPLY FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR CAP-1002 BASED ON UPDATED GUIDANCE RECENTLY ISSUED BY FDA.  Full Article

Capricor Therapeutics reports Q3 loss per share $0.12
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Capricor Therapeutics Inc ::Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program.Q3 loss per share $0.12.  Full Article

Capricor Therapeutics presents positive six-month results in duchenne muscular dystrophy at WMS International Congress
Wednesday, 4 Oct 2017 

Oct 4 (Reuters) - Capricor Therapeutics Inc : :Capricor Therapeutics presents positive six-month results in duchenne muscular dystrophy at World Muscle Society International Congress.Capricor Therapeutics Inc - ‍treatment with CAP-1002 was generally safe and well-tolerated over initial six-month follow-up period of hope trial​.  Full Article

Capricor Therapeutics Q2 loss per share $0.16
Thursday, 10 Aug 2017 

Aug 10 (Reuters) - Capricor Therapeutics Inc :Capricor Therapeutics reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.16.Capricor Therapeutics Inc - announced statistically-significant improvements in skeletal and cardiac muscle function in patients treated with CAP-1002.Capricor Therapeutics Inc - plans to commence clinical trial of I.V. CAP-1002 in Duchenne Muscular Dystrophy in the fourth quarter.  Full Article

UPDATE 1-U.S. drug developer Capricor places Duchenne drug trial on hold

Dec 26 Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.